TABLE 2.
Summary of Statistical Analysis of OS
Population | Methodology | OS Hazard Ratio (90% CI) Gemcitabine/Berzosertib v Gemcitabine Alone |
---|---|---|
Overall | ITT | 0.79 (0.52 to 1.20) |
Exclude crossover | 0.60 (0.38 to 0.94) | |
CXO | 0.73 (0.47 to 1.15) | |
TVC | 0.81 (0.55 to 1.20) | |
IPCW | 0.58 (0.37 to 0.89) | |
PFI ≤3 months | ITT | 0.48 (0.22 to 1.01) |
Exclude crossover | 0.26 (0.11 to 0.62) | |
CXO | 0.33 (0.13 to 0.83) | |
TVC | 0.59 (0.29 to 1.21) | |
IPCW | 0.29 (0.12 to 0.70) | |
ATM-negative/ATM-low | ITT | 0.50 (0.23 to 1.08) |
Exclude crossover | 0.32 (0.14 to 0.73) | |
CXO | 0.43 (0.19 to 0.96) | |
TVC | 0.60 (0.29 to 1.22) | |
IPCW | 0.34 (0.16 to 0.72) | |
RS-low | ITT | 0.77 (0.40 to 1.49) |
Exclude crossover | 0.39 (0.19 to 0.82) | |
CXO | 0.60 (0.27 to 1.33) | |
TVC | 0.57 (0.31 to 1.08) | |
IPCW | 0.49 (0.23 to 1.04) |
Abbreviations: CXO, censored at crossover; IPCW, inverse probability of censor weighting; ITT, intent-to-treat; OS, overall survival; PFI, platinum-free interval; RS, replication stress; TVC, time-varying covariate.